Antiviral Activity of and Resistance to Lamivudine in Combination With Zidovudine, Stavudine, or Didanosine
Status:
Completed
Trial end date:
1998-03-01
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy, safety, and pharmacokinetics of lamivudine (3TC) combined with
zidovudine (AZT), stavudine (d4T), or didanosine (ddI) in comparison with d4T or ddI
monotherapy in HIV-infected patients with no prior nucleoside therapy.
3TC may be uniquely effective in combination with AZT due to the interaction of AZT and 3TC
resistance mutations. One explanation is that the M184V mutation, which confers resistance to
3TC, suppresses AZT resistance. This benefit of 3TC may not extend to combination therapy
with other nucleoside analogs.
Phase:
Phase 2
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)